Omicron News and Research

RSS

Fourth dose of COVID-19 vaccine reduced death among hospitalized patients during Omicron wave in Israel

Researchers investigated the effect of a fourth dose of the coronavirus disease 2019 (COVID-19) vaccine in patients with severe disease symptoms.

2 May 2022

Study estimates the elevated risks of COVID-19 breakthrough infection and hospitalization in fully vaccinated individuals with comorbidities

The current study aimed to understand both the risk of breakthrough infection and severe outcomes in this population.

2 May 2022

Higher contact among vaccinated people may negatively influence vaccine effectiveness

In a new study, researchers reported that contact among vaccinated people could influence the effectiveness of COVID-19 vaccines.

2 May 2022

Development of prioritization tool to further the role of equity in global COVID-19 vaccine allocation

A new study proposed a conceptual framework (COVID-NEEDS) that assessed whether vaccine needs are impacted by social, health, and economic conditions of COVID-19 and associated NPIs.

2 May 2022

Higher vaccination coverage associated with lower rates of population-level COVID-19 mortality and incidence in the US

By using data representing 80% of the US population, researchers have found that increased vaccination coverage against COVID-19 can be linked to a reduced incidence of cases and deaths.

2 May 2022

SARS-CoV-2-specific T cells are broader after vaccination than after infection

In a recent study published in the Nature Microbiology journal, researchers investigated the characteristics of coronavirus disease 2019 (COVID-19) infection in convalescent and vaccinated individuals.

1 May 2022

$Can fractional doses of COVID-19 vaccines protect against SARS-CoV-2?$

Can fractional doses of COVID-19 vaccines protect against SARS-CoV-2?

A recent research paper posted to the Research Square* preprint server assessed the dose fractionation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

1 May 2022

Antibody cocktail shows synergetic effects against SARS-CoV-2 Omicron in vitro and in vivo

A recent research paper posted to the bioRxiv* preprint server demonstrated that a cocktail of two synergetic antibodies extensively neutralized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including Omicron BA.1 and BA.2.

1 May 2022

Safety and immunogenicity of three-dose vaccination with the Pfizer/BioNtech SARS-CoV-2 mRNA vaccine

A recent article published in the Med journal reported that the SARS-CoV-2 booster vaccinations enhance the SARS-CoV-2 Omicron sublineage neutralizations.

29 Apr 2022

Clinical characteristics of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

Researchers examined the characteristics and outcomes of COVID-19 in immunocompromised patients.

29 Apr 2022

Chimeric Delta-Omicron RBD-dimer vaccine found to be effective against SARS-CoV-2 variants

In a new study, researchers described their self-designed chimeric receptor-binding domain-dimer vaccine approach to adapt SARS-CoV-2 variants of concern and variants of interest.

29 Apr 2022

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Researchers examined the efficiency of the main protease (Mpro) inhibitor against SARS-CoV-2.

29 Apr 2022

Study finds curcumin is a potential therapeutic agent against the Omicron variant of SARS-CoV-2

A recent study demonstrated that the phytochemical curcumin is a potent therapeutic prospect against the SARS-CoV-2 Omicron variant

29 Apr 2022

Behavior differences led to higher COVID-19 mortality rates in the southern U.S.

During the pre-Omicron phases of the COVID-19 pandemic, regions of the U.S. had markedly different mortality rates, primarily due to differences in mask use, school attendance, social distancing, and other behaviors.

28 Apr 2022

Therapeutic promise of CAR-T cell bispecific engagers against SARS-CoV-2

A new paper describes a novel method, using a specific molecule to engage T cell receptors and the virus receptor, the angiotensin-converting enzyme 2, at the same time.

28 Apr 2022

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Researchers identified a human monoclonal antibody (mAb), 87G7, with in vitro neutralizing activity against several SARS-CoV-2 VOCs, including Alpha, Beta, Gamma, Delta, and Omicron.

28 Apr 2022

Nearly 60% of Americans infected by Omicron

A recent study published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR) assessed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-induced viral antibodies (Abs) seroprevalence in the United States (US).

28 Apr 2022

Omicron News and Research

Fourth dose of COVID-19 vaccine reduced death among hospitalized patients during Omicron wave in Israel

Study estimates the elevated risks of COVID-19 breakthrough infection and hospitalization in fully vaccinated individuals with comorbidities

Higher contact among vaccinated people may negatively influence vaccine effectiveness

Development of prioritization tool to further the role of equity in global COVID-19 vaccine allocation

Higher vaccination coverage associated with lower rates of population-level COVID-19 mortality and incidence in the US

SARS-CoV-2-specific T cells are broader after vaccination than after infection

Can fractional doses of COVID-19 vaccines protect against SARS-CoV-2?

Antibody cocktail shows synergetic effects against SARS-CoV-2 Omicron in vitro and in vivo

Safety and immunogenicity of three-dose vaccination with the Pfizer/BioNtech SARS-CoV-2 mRNA vaccine

Clinical characteristics of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

Chimeric Delta-Omicron RBD-dimer vaccine found to be effective against SARS-CoV-2 variants

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Study finds curcumin is a potential therapeutic agent against the Omicron variant of SARS-CoV-2

Behavior differences led to higher COVID-19 mortality rates in the southern U.S.

Therapeutic promise of CAR-T cell bispecific engagers against SARS-CoV-2

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Nearly 60% of Americans infected by Omicron

Researchers demonstrate the efficiency of T-cell immune response against the Omicron variant

Scientists explore mixing of unvaccinated and vaccinated and implications for SARS-CoV-2 transmission

Discovery of novel antibody that targets shared epitope on SARS-CoV-2 variants

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News